打开APP

Oncolytics抗肿瘤药物Reolysin二期研究反映良好

  1. Oncolytics
  2. Reolysin
  3. 抗肿瘤药物

来源:生物谷 2013-09-12 09:44

2013年9月11日讯 /生物谷BIOON/ --加拿大制药公司Oncolytics研制的溶瘤病毒药物Reolysin在一项有25名患者参与的二期研究中被发现有高达92%的有效率。有23名患者的肿瘤尺寸减小。消息一经公布,公司股价应声上扬,不过关于这种药物具体的中期研究报告需要在今年晚些时候才能得到,目前公司正在着手开始三期研究的准备。

2013年9月11日讯 /生物谷BIOON/ --加拿大制药公司Oncolytics研制的溶瘤病毒药物Reolysin在一项有25名患者参与的二期研究中被发现有高达92%的有效率。有23名患者的肿瘤尺寸减小。消息一经公布,公司股价应声上扬,不过关于这种药物具体的中期研究报告需要在今年晚些时候才能得到,目前公司正在着手开始三期研究的准备。不过一些投资分析人士也质疑此次研究患者规模过小,对研究数据的有效性提出质疑。(生物谷Bioon.com)

详细英文报道:

Shares of Canada's Oncolytics ($ONCY) surged again this morning after the biotech reported out a final analysis on its tumor virus Reolysin, showing a 92% response rate among a small group of 25 patients enrolled in a Phase II study.

Out of that 25, all but two of the patients demonstrated a reduction in tumor size. The mean shrinkage rate was 32.7% with 10 patients seeing a partial response and 13 showing signs of stable disease. And its stock quickly spiked 20% on the news, which followed a report on interim data back in February. Final progression-free survival and safety data for the study will be reported later in 2013.

Oncolytics also has a Phase III study of Reolysin underway for head and neck cancer, which has attracted considerable interest in the small-investor crowd drawn to the high-stakes world of drug development. Some analysts, including TheStreet's Adam Feuerstein, have been critical of the company's data so far, questioning the data's accuracy and its ultimate usefulness in gaining a possible regulatory approval. Small cap biotechs in general have a miserable record at gaining approvals for cancer drugs.

But none of that skepticism, of course, was on display in the company's release.

"We are thrilled to have demonstrated 92% overall tumour shrinkage in this group of patients," said Oncolytics CEO Brad Thompson. "Squamous cell carcinoma of the lung is notoriously difficult to treat, and these results support further investigation of Reolysin in randomized clinical trials for this indication."

Investigators for the biotech took a common respiratory virus and in this case added a pair of chemotherapies. According to the biotech, this approach allows the virus to infect cancer cells and essentially force it to self destruct. It's one of several cancer viruses in the clinic, including Amgen's ($AMGN) work on talimogene laherparepvec--the oncolytic virus known as T-Vec--which is being studied as a treatment for melanoma.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->